Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

VKBK Mesu, WM Kalonji, C Bardonneau, OV Mordt… - The Lancet, 2018 - thelancet.com
Background Few therapeutic options are available to treat the late-stage of human African
trypanosomiasis, a neglected tropical disease, caused by Trypanosoma brucei gambiense …

[HTML][HTML] Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

VKBK Mesu, WM Kalonji, C Bardonneau… - The Lancet Global …, 2021 - thelancet.com
Background Staging and treatment of human African trypanosomiasis caused by
Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal …

[HTML][HTML] Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label …

VKB Kumeso, WM Kalonji, S Rembry… - The Lancet infectious …, 2023 - thelancet.com
Summary Background Human African trypanosomiasis caused by Trypanosoma brucei
gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission …

New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice

AK Lindner, V Lejon, F Chappuis, J Seixas… - The Lancet Infectious …, 2020 - thelancet.com
Human African trypanosomiasis caused by Trypanosoma brucei gambiense is a parasitic
infection that usually progresses to coma and death unless treated. WHO has updated its …

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non …

G Priotto, S Kasparian, W Mutombo, D Ngouama… - The Lancet, 2009 - thelancet.com
Summary Background Human African trypanosomiasis (HAT; sleeping sickness) caused by
Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients …

[HTML][HTML] Recent progress in diagnosis and treatment of Human African Trypanosomiasis has made the elimination of this disease a realistic target by 2030

A Álvarez-Rodríguez, BK Jin, M Radwanska… - Frontiers in …, 2022 - frontiersin.org
Human African Trypanosomiasis (HAT) is caused by unicellular flagellated protozoan
parasites of the genus Trypanosoma brucei. The subspecies T. b. gambiense is mainly …

Treatment options for second-stage gambiense human African trypanosomiasis

G Eperon, M Balasegaram, J Potet… - Expert review of anti …, 2014 - Taylor & Francis
Treatment of second-stage gambiense human African trypanosomiasis relied on toxic
arsenic-based derivatives for over 50 years. The availability and subsequent use of …

Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic …

E Alirol, D Schrumpf, J Amici Heradi… - Clinical infectious …, 2013 - academic.oup.com
Background. Existing diagnostic and treatment tools for human African trypanosomiasis
(HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy …

[HTML][HTML] Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies

A Tarral, S Blesson, OV Mordt, E Torreele… - Clinical …, 2014 - Springer
Abstract Background and Objectives Fexinidazole is a 5-nitroimidazole recently included in
a clinical efficacy trial as an oral drug for the treatment of human African trypanosomiasis …

[HTML][HTML] New drugs for human African trypanosomiasis: a twenty first century success story

EA Dickie, F Giordani, MK Gould, P Mäser… - Tropical medicine and …, 2020 - mdpi.com
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging
across many parts of Africa. Resistance to existing drugs was emerging, and many programs …